Skip to main content

Table 4 Postoperative in-hospital complications

From: Effect of ramosetron on QTc interval: a randomised controlled trial in patients undergoing off-pump coronary artery bypass surgery

 

Ramosetron (n = 51)

Placebo (n = 52)

RR (95 % CI)

P value

Atrial fibrillation

11 (21.6 %)

14 (26.9 %)

0.80 (0.40 to 1.60)

0.647

Atrial flutter

1 (2.0 %)

1 (1.9 %)

1.02 (0.07 to 15.87)

1.000

Ventricular tachycardia

0 (0.0 %)

0 (0.0 %)

  

Ventricular fibrillation

0 (0.0 %)

0 (0.0 %)

  

Bradycardia (heart rate <50 beats/min)

0 (0.0 %)

2 (3.8 %)

 

0.495

Tachycardia (heart rate > 100 beats/min)

5 (9.8 %)

8 (15.4 %)

0.64 (0.22 to 1.82)

0.555

Death from cardiac causes

0 (0.0 %)

0 (0.0 %)

  

Myocardial infarction

0 (0.0 %)

0 (0.0 %)

  

Unplanned coronary revascularisation

0 (0.0 %)

1 (1.9 %)

 

1.000

Stroke

1 (2.0 %)

1 (1.9 %)

1.02 (0.07 to 15.87)

1.000

Intensive care unit length of stay (day)

2 (1 to 3)

2 (1 to 4)

 

0.912

Hospital length of stay (day)

9 (7 to 13)

8.5 (7 to 13.75)

 

0.350

  1. Data are presented as number (proportion) or median (IQR). CI, confidence interval; RR, relative risk